Revenue Breakdown
Composition ()
No data
Revenue Streams
GeneDx Holdings Corp (WGS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Patients with third party insurance, accounting for 81.4% of total sales, equivalent to $95.02M. Other significant revenue streams include Institutional customers and Other. Understanding this composition is critical for investors evaluating how WGS navigates market cycles within the Healthcare Facilities & Services industry.
Profitability & Margins
Evaluating the bottom line, GeneDx Holdings Corp maintains a gross margin of 72.40%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2.78%, while the net margin is -6.54%. These profitability ratios, combined with a Return on Equity (ROE) of 0.84%, provide a clear picture of how effectively WGS converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, WGS competes directly with industry leaders such as LFST and CON. With a market capitalization of $2.70B, it holds a significant position in the sector. When comparing efficiency, WGS's gross margin of 72.40% stands against LFST's 100.00% and CON's 25.73%. Such benchmarking helps identify whether GeneDx Holdings Corp is trading at a premium or discount relative to its financial performance.
